LOS ANGELES, CA — When a 67-year-old former shipyard worker from Long Beach received his pleural mesothelioma diagnosis in late 2024, his oncologist at a community hospital told him the median survival was roughly 12 months. Six months later, after transferring care to a major California cancer center, he was enrolled in a combination immunotherapy trial. He's now past the 18-month mark and still working part-time. His story isn't unique anymore. Across California, a convergence of clinical research, specialized surgical programs, and expanded immunotherapy access is quietly changing what's possible for mesothelioma patients, even those diagnosed at advanced stages.
California has emerged as one of the most active states for mesothelioma treatment development, driven largely by the research programs at UCLA Health, UC San Francisco, City of Hope in Duarte, and Stanford Health Care. These institutions collectively host dozens of active mesothelioma-related clinical trials at any given time, according to the National Cancer Institute's clinical trials database, which listed more than 40 open mesothelioma studies at California institutions as of early 2026 [1]. For patients in a state where asbestos exposure historically ran high, particularly in shipbuilding, oil refining, and construction industries, that concentration of expertise matters enormously.
Why California's Treatment Landscape Stands Apart
The shift accelerated significantly after the FDA approved nivolumab plus ipilimumab (Opdivo plus Yervoy) as a first-line treatment for unresectable pleural mesothelioma in October 2020, based on the CheckMate 743 trial results published in The Lancet [2]. That approval gave oncologists a chemotherapy-free option for the first time in nearly two decades, and California's major centers moved quickly to build protocols around it. The CheckMate 743 data showed that the dual immunotherapy combination improved median overall survival to 18.1 months compared to 14.1 months with standard platinum-based chemotherapy, with particularly strong results in non-epithelioid subtypes that had historically responded poorly to any treatment.
But the institutions leading California's mesothelioma care aren't stopping there. UC San Francisco's thoracic oncology program has been investigating second-line immunotherapy combinations and tumor-infiltrating lymphocyte therapies. City of Hope has one of the country's more active programs in CAR-T cell research for solid tumors, including mesothelin-targeted approaches directly relevant to mesothelioma. Stanford has contributed research into the tumor microenvironment that is shaping how oncologists understand why some mesothelioma patients respond dramatically to immunotherapy while others don't respond at all [3].
What I hear from patients going through this is that the distance between a community oncologist and a mesothelioma specialist can feel like crossing a continent. The difference isn't just access to trials. It's the depth of experience, the multidisciplinary teams that include thoracic surgeons, pulmonologists, pathologists who specialize in mesothelioma subtypes, and palliative care specialists who help manage symptoms alongside aggressive treatment. That integrated model is what California's leading centers do well.
For patients and families navigating a new diagnosis, understanding which California facility is best positioned to treat your specific subtype, whether epithelioid, sarcomatoid, or biphasic, is among the most critical early decisions. Epithelioid tumors generally respond better to both surgery and immunotherapy. Sarcomatoid and biphasic tumors have historically been harder to treat, but the CheckMate 743 data showed the nivolumab-ipilimumab combination actually produced its most dramatic survival improvements in non-epithelioid patients, a finding that has reshaped treatment conversations at every major center.
What Getting to a California Specialist Actually Requires
Accessing California's leading mesothelioma programs isn't automatic. Many patients, particularly those diagnosed at community hospitals or in rural areas of the state, don't receive an automatic referral to a specialized center. Requesting a second opinion, or a formal transfer of care, is something many patients hesitate to do, often out of concern for offending their current physician or disrupting their treatment timeline. The most important step you can take right now, if you've received a mesothelioma diagnosis in California, is to contact one of the state's NCI-designated cancer centers directly and ask about their mesothelioma program. These centers accept self-referrals, and the intake process often moves faster than patients expect.
There are also practical financial considerations. Many patients diagnosed with mesothelioma were exposed to asbestos through their work, and compensation options/) including asbestos trust fund claims may help cover the cost of travel, lodging, and treatment at a specialized center. Many patients and families I've worked with are surprised to learn that trust fund claims can often be filed without litigation and on relatively short timelines. Our compensation estimator can provide an initial picture of what may be available based on your exposure history.
For veterans, who account for roughly 30 percent of all mesothelioma diagnoses nationally according to the Mesothelioma Applied Research Foundation, the VA has established partnerships with several California centers, and dedicated veterans' resources exist to help navigate both VA benefits and civilian treatment options simultaneously.
What This Means: California's concentration of mesothelioma expertise, clinical trials, and immunotherapy programs means that patients in the state have access to some of the most advanced care available anywhere. Getting to that care requires proactive steps, including seeking specialized referrals and exploring financial assistance options, but the outcomes data increasingly suggests that effort is worth making.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance specific to your situation.
